SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OCATA THERAPEUTICS
OCAT 8.4700.0%Feb 11 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: FJB12/13/2012 5:56:38 PM
   of 134
 
First human trials involving reprogrammed stem cells could come next year

By Chris Welch on December 13, 2012 04:31 pm Email @chriswelch5COMMENTS



John B. Gurdon and Shinya Yamanaka earned a Nobel Prize for breakthroughs that came from their decades of stem cell research. Now it appears their work may soon change lives. The Wall Street Journal reports that a biotechnology company plans to seek regulatory approval as early as tomorrow for human trials involving reprogrammed stem cells. Unlike traditional stem cells, which are sourced from destroyed human embryos and thus embroiled in ethical controversy, reprogrammed cells can come from other areas of the body such as your skin.

Advanced Cell Technology hopes to harness the potential of these reprogrammed cells to develop better treatment options for patients suffering from leukemia and anemia. Individuals with certain types of those diseases routinely need platelet infusions, which maintain their body's blood-clotting ability. Unfortunately, it's been found that our bodies can sometimes become resistant to donated blood. Creating platelets from a patient's own cells solves this medical hurdle. If the U.S. Food and Drug Administration grants its request, ACT could begin testing by the end of 2013.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News